Company Overview and News

 
Medlab Clinical on track for analytical release of Nanabis pain management medicine

2018-03-02 proactiveinvestors.com.au
Medlab Clinical Ltd (ASX:MDC), a developer of cannabis based medicines, has made solid progress with its proprietary pain management product, Nanabis.
Upvote Downvote

 
Medlab Clinical attracts $24 million for cannabis based medicine

2018-01-26 proactiveinvestors.com.au
Medlab Clinical Ltd (ASX:MDC) has successfully completed a placement of shares to institutional and sophisticated investors to raise $24 million at $0.09 per share.
Upvote Downvote

 
Medlab Clinical wins patent for its unique anti-depression product

2017-09-18 proactiveinvestors.com.au
Medlab Clinical Ltd (ASX:MDC) has been granted a 20-year patent covering the Australian market for its probiotic product, NRGBiotic™.
Upvote Downvote

 
Medlab Clinical establishes strategic alliance for nutritional products

2017-07-13 proactiveinvestors.com.au
Medlab Clinical Ltd (ASX:MDC) has established a strategic alliance with Heritage Brands, to develop over-the-counter well-being solutions for the pharmacy retail channel.
Upvote Downvote

 
Medlab Clinical to begin trials of cannabis based medicines

2017-06-19 proactiveinvestors.com.au
Medlab Clinical (ASX:MDC) has received approvals to begin human trials of two different cannabis based medicines – NanaBis and NanaBidial.
Upvote Downvote

 
Brian Gaynor: Cannabis stocks don't take long to get high

2017-05-12 nzherald.co.nz
Global sharemarkets are going to pot as a large number of marijuana companies have listed in recent years, including on the Australian sharemarket.
Upvote Downvote

 
Medlab Clinical initiates study of cholesterol lowering oral spray

2017-03-06 proactiveinvestors.com.au
Medlab Clinical (ASX:MDC) has signed an agreement to initiate a study to compare how its atorvastatin oral spray compares with statin tablets, like Lipitor, the off-patent market leader.
Upvote Downvote

 
Medlab Clinical to start Australia’s first trial of cannabis for oncology patients

2017-02-22 proactiveinvestors.com.au
Medlab Clinical (ASX:MDC) is completing the final steps to start Australia’s first clinical trial using cannabis for oncology patients suffering intractable pain.
Upvote Downvote

 
Latest Reports on Aphria, dynaCERT, Avrupa Minerals, and 92 Resources

2016-09-13 accesswire
NEW YORK, NY / ACCESSWIRE / September 13, 2016 / Canadian markets were relatively flat Monday as financials fell on retreats in overseas markets, while few energy stocks rose on an uptick in commodity prices. The S&P/TSX Composite Index gained 0.39 percent to close at 14,597.06, while the S&P/TSX Venture Composite Index gained 0.22 percent to close at 813.94. The Materials sector posted a gain of 1.
Upvote Downvote

 
Medlab Clinical Ltd initiates Phase 2a after positive anti-depression results

2016-08-30 proactiveinvestors.com.au
Medlab Clinical Ltd (ASX:MDC) will initiate Phase 2a human trial of its anti-depression therapy following encouraging results from Phase 1. 
Upvote Downvote

 
Medlab and Aphria Complete Cannabis Supply Deal Ahead of Cannabis Human Trial

2016-08-22 marketwired
LEAMINGTON, ONTARIO--(Marketwired - Aug. 22, 2016) - Medical life science company, Medlab Clinical Limited (ASX:MDC), has signed a significant cannabis supply agreement with Canadian licenced producer of medical marijuana, Aphria Inc. (TSX VENTURE:APH)(OTCQB:APHQF).
Upvote Downvote

 
AusCann in medicinal cannabis alliance

2016-05-09 news.theage.com.au
JavaScript disabled. Please enable JavaScript to use My News, My Clippings, My Comments and user settings.
Upvote Downvote

 
AusCann in medicinal cannabis alliance

2016-05-09 news.smh.com.au
JavaScript disabled. Please enable JavaScript to use My News, My Clippings, My Comments and user settings.
Upvote Downvote

 
 
Another cannabis company set to list

2016-03-17 news.theage.com.au
JavaScript disabled. Please enable JavaScript to use My News, My Clippings, My Comments and user settings.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...